Cytosorbents Corporation (CTSO)Healthcare | Medical Devices | Princeton, United States | NasdaqCM
0.66 USD
+0.05
(8.197%)
⇧
(April 17, 2026, 4 p.m.
EDT)
After hours: 0.64 -0.02 (-0.023%) ⇩ (April 17, 2026, 5:46 p.m. EDT) Short-term: ☆☆☆☆☆ | Long-term: ☆☆☆☆☆ | Dividends: ☆☆☆☆☆ |
Hot Take | April 19, 2026, 1:09 a.m. EDT
CTSO is in a high-risk existential crisis zone where fundamental deterioration (severe profitability issues, negative cash flow, and debt distress) is overshadowing any potential business upside. The company has triggered Nasdaq compliance delisting risks and received an extension, marking its inability to regain compliance on its own. With a massive short interest (18.75%) and a betting-the-company odds setup (analysts valuing it at ~$5 post-recovery vs current ~$0.66), this is a speculative trap rather than an investment. The near-term trend is structurally bearish as the market prices in delisting or extinction. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.065625 |
| AutoARIMA | 0.070076 |
| AutoETS | 0.072020 |
| MSTL | 0.089480 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 46% |
| H-stat | 6.46 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.371 |
| Excess Kurtosis | -0.02 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 493.156 |
| Revenue per Share | 0.596 |
| Market Cap | 41,450,844 |
| Forward P/E | Infinity |
| Beta | 1.48 |
| Profit Margins | -22.12% |
| Website | https://www.cytosorbents.com |
As of April 19, 2026, 1:09 a.m. EDT: Options activity is negligible with extremely low Open Interest (Total Exp Vol=0 or 1 contracts) and zero Implied Volatility for most strikes across all expirations (May, Aug, Nov 2026). There is no directional flow signal, either bullish or bearish, suggesting a complete absence of speculative positioning due to the micro-cap status and liquidity constraints. IV is effectively zero or non-reportable.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.39449543 |
| Address1 | 305 College Road East |
| All Time High | 98.75 |
| All Time Low | 0.499 |
| Ask | 0.6951 |
| Ask Size | 1 |
| Average Analyst Rating | 2.0 - Buy |
| Average Daily Volume10 Day | 70,400 |
| Average Daily Volume3 Month | 88,754 |
| Average Volume | 88,754 |
| Average Volume10Days | 70,400 |
| Beta | 1.476 |
| Bid | 0.6103 |
| Bid Size | 1 |
| Book Value | 0.094 |
| City | Princeton |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 0.66 |
| Current Ratio | 2.125 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 0.67 |
| Day Low | 0.6 |
| Debt To Equity | 493.156 |
| Display Name | Cytosorbents |
| Earnings Call Timestamp End | 1,774,470,600 |
| Earnings Call Timestamp Start | 1,774,470,600 |
| Earnings Timestamp | 1,774,468,800 |
| Earnings Timestamp End | 1,778,702,400 |
| Earnings Timestamp Start | 1,778,702,400 |
| Ebitda | -12,743,000 |
| Ebitda Margins | -0.34382 |
| Enterprise To Ebitda | -5.042 |
| Enterprise To Revenue | 1.733 |
| Enterprise Value | 64,244,000 |
| Eps Forward | 0.0 |
| Eps Trailing Twelve Months | -0.13 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fax | 732 329 8650 |
| Fifty Day Average | 0.66416 |
| Fifty Day Average Change | -0.004159987 |
| Fifty Day Average Change Percent | -0.0062635313 |
| Fifty Two Week Change Percent | -39.449543 |
| Fifty Two Week High | 1.39 |
| Fifty Two Week High Change | -0.72999996 |
| Fifty Two Week High Change Percent | -0.5251798 |
| Fifty Two Week Low | 0.499 |
| Fifty Two Week Low Change | 0.16100001 |
| Fifty Two Week Low Change Percent | 0.3226453 |
| Fifty Two Week Range | 0.499 - 1.39 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,155,043,800,000 |
| Float Shares | 54,819,864 |
| Forward Eps | 0.0 |
| Forward P E | Infinity |
| Free Cashflow | -2,071,875 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 129 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.71476 |
| Gross Profits | 26,491,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.15630001 |
| Held Percent Institutions | 0.27071 |
| Implied Shares Outstanding | 62,804,305 |
| Industry | Medical Devices |
| Industry Disp | Medical Devices |
| Industry Key | medical-devices |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,417,737,600 |
| Last Split Factor | 1:25 |
| Long Business Summary | Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. The company's flagship product is CytoSorb, an extracorporeal blood purification cartridge for the treatment of massive inflammation, organ failure, cardiothoracic surgery to remove antithrombotic drugs and inflammatory mediators that can lead to postoperative complications, such as severe bleeding, shock, failure to wean from mechanical ventilation, sepsis, and multiple organ failure; DrugSorb-ATR, an antithrombotic removal system; VetResQ, a broad-spectrum blood purification adsorber for the treatment of septic shock, toxic shock syndrome, toxin-mediated diseases, pancreatitis, trauma, liver failure, heat stroke, and lung injury in animals; PuriFi, an advanced hemoperfusion pump for blood purification therapies; and ECOS-300CY, an ex vivo organ perfusion system to preserve or improve the health and quality of harvested solid organs to be transplanted. In addition, it develops HemoDefend-BGA, a blood purification technology platform to reduce anti-A and anti-B antibodies in plasma and whole blood. The company was formerly known as MedaSorb Technologies Corporation and changed its name to Cytosorbents Corporation in May 2010. Cytosorbents Corporation was founded in 1997 and is headquartered in Princeton, New Jersey. |
| Long Name | Cytosorbents Corporation |
| Market | us_market |
| Market Cap | 41,450,844 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_628213 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | -8,198,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 41,457,121 |
| Number Of Analyst Opinions | 3 |
| Open | 0.61 |
| Operating Cashflow | -12,377,000 |
| Operating Margins | -0.4387 |
| Payout Ratio | 0.0 |
| Phone | 732 329 8885 |
| Post Market Change | -0.022600055 |
| Post Market Change Percent | -3.4242506 |
| Post Market Price | 0.6374 |
| Post Market Time | 1,776,462,376 |
| Previous Close | 0.61 |
| Price Hint | 4 |
| Price To Book | 7.021277 |
| Price To Sales Trailing12 Months | 1.1183888 |
| Profit Margins | -0.22118999 |
| Quick Ratio | 1.421 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | buy |
| Recommendation Mean | 2.0 |
| Region | US |
| Regular Market Change | 0.05 |
| Regular Market Change Percent | 8.19672 |
| Regular Market Day High | 0.67 |
| Regular Market Day Low | 0.6 |
| Regular Market Day Range | 0.6 - 0.67 |
| Regular Market Open | 0.61 |
| Regular Market Previous Close | 0.61 |
| Regular Market Price | 0.66 |
| Regular Market Time | 1,776,456,000 |
| Regular Market Volume | 125,890 |
| Return On Assets | -0.19441 |
| Return On Equity | -0.96389997 |
| Revenue Growth | 0.009 |
| Revenue Per Share | 0.596 |
| Sand P52 Week Change | 0.38150132 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 62,804,305 |
| Shares Percent Shares Out | 0.0322 |
| Shares Short | 2,020,680 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 2,000,812 |
| Short Name | Cytosorbents Corporation |
| Short Percent Of Float | 0.035 |
| Short Ratio | 18.75 |
| Source Interval | 15 |
| State | NJ |
| Symbol | CTSO |
| Target High Price | 10.0 |
| Target Low Price | 0.75 |
| Target Mean Price | 5.25 |
| Target Median Price | 5.0 |
| Total Cash | 6,249,000 |
| Total Cash Per Share | 0.1 |
| Total Debt | 29,111,000 |
| Total Revenue | 37,063,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.13 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 0.799095 |
| Two Hundred Day Average Change | -0.13909495 |
| Two Hundred Day Average Change Percent | -0.1740656 |
| Type Disp | Equity |
| Volume | 125,890 |
| Website | https://www.cytosorbents.com |
| Zip | 8,540 |